AUTHOR=Crans René A. J. , Wouters Elise , Valle-León Marta , Taura Jaume , Massari Caio M. , Fernández-Dueñas Víctor , Stove Christophe P. , Ciruela Francisco 

TITLE=Striatal Dopamine D2-Muscarinic Acetylcholine M1 Receptor–Receptor Interaction in a Model of Movement Disorders

JOURNAL=Frontiers in Pharmacology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00194

DOI=10.3389/fphar.2020.00194

ISSN=1663-9812

ABSTRACT=<p>Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor control deficits, which is associated with the loss of striatal dopaminergic neurons from the substantia nigra. In parallel to dopaminergic denervation, there is an increase of acetylcholine within the striatum, resulting in a striatal dopaminergic–cholinergic neurotransmission imbalance. Currently, available PD pharmacotherapy (e.g., prodopaminergic drugs) does not reinstate the altered dopaminergic–cholinergic balance. In addition, it can eventually elicit cholinergic-related adverse effects. Here, we investigated the interplay between dopaminergic and cholinergic systems by assessing the physical and functional interaction of dopamine D<sub>2</sub> and muscarinic acetylcholine M<sub>1</sub> receptors (D<sub>2</sub>R and M<sub>1</sub>R, respectively), both expressed at striatopallidal medium spiny neurons. First, we provided evidence for the existence of D<sub>2</sub>R–M<sub>1</sub>R complexes via biochemical (i.e., co-immunoprecipitation) and biophysical (i.e., BRET<sup>1</sup> and NanoBiT<sup>®</sup>) assays, performed in transiently transfected HEK293T cells. Subsequently, a D<sub>2</sub>R–M<sub>1</sub>R co-distribution in the mouse striatum was observed through double-immunofluorescence staining and AlphaLISA<sup>®</sup> immunoassay. Finally, we evaluated the functional interplay between both receptors via behavioral studies, by implementing the classical acute reserpine pharmacological animal model of experimental parkinsonism. Reserpinized mice were administered with a D<sub>2</sub>R-selective agonist (sumanirole) and/or an M<sub>1</sub>R-selective antagonist (VU0255035), and alterations in PD-related behavioral tasks (i.e., locomotor activity) were evaluated. Importantly, VU0255035 (10 mg/kg) potentiated the antiparkinsonian-like effects (i.e., increased locomotor activity and decreased catalepsy) of an ineffective sumanirole dose (3 mg/kg). Altogether, our data suggest the existence of putative striatal D<sub>2</sub>R/M<sub>1</sub>R heteromers, which might be a relevant target to manage PD motor impairments with fewer adverse effects.</p>